RU2013123646A - Комбинированная композиция - Google Patents

Комбинированная композиция Download PDF

Info

Publication number
RU2013123646A
RU2013123646A RU2013123646/15A RU2013123646A RU2013123646A RU 2013123646 A RU2013123646 A RU 2013123646A RU 2013123646/15 A RU2013123646/15 A RU 2013123646/15A RU 2013123646 A RU2013123646 A RU 2013123646A RU 2013123646 A RU2013123646 A RU 2013123646A
Authority
RU
Russia
Prior art keywords
paracetamol
ibuprofen
combination
composition
accordance
Prior art date
Application number
RU2013123646/15A
Other languages
English (en)
Russian (ru)
Inventor
Хартли Кэмпбелл АТКИНСОН
Original Assignee
АФТ Фармасьютикалз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2013123646(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by АФТ Фармасьютикалз Лимитед filed Critical АФТ Фармасьютикалз Лимитед
Publication of RU2013123646A publication Critical patent/RU2013123646A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
RU2013123646/15A 2010-11-04 2011-10-26 Комбинированная композиция RU2013123646A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
NZ589011 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2015103107A Division RU2707089C2 (ru) 2010-11-04 2011-10-26 Комбинированная композиция

Publications (1)

Publication Number Publication Date
RU2013123646A true RU2013123646A (ru) 2014-12-10

Family

ID=46024668

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015103107A RU2707089C2 (ru) 2010-11-04 2011-10-26 Комбинированная композиция
RU2013123646/15A RU2013123646A (ru) 2010-11-04 2011-10-26 Комбинированная композиция

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2015103107A RU2707089C2 (ru) 2010-11-04 2011-10-26 Комбинированная композиция

Country Status (28)

Country Link
US (6) US20130225685A1 (enExample)
EP (1) EP2635269B1 (enExample)
JP (2) JP2013541583A (enExample)
KR (1) KR101900520B1 (enExample)
CN (2) CN103298464A (enExample)
AU (1) AU2011324137B2 (enExample)
BR (1) BR112013010829B8 (enExample)
CA (1) CA2814057C (enExample)
CL (1) CL2013001250A1 (enExample)
CO (1) CO6771406A2 (enExample)
CY (1) CY1123398T1 (enExample)
DK (1) DK2635269T3 (enExample)
ES (1) ES2742373T3 (enExample)
HR (1) HRP20191489T1 (enExample)
HU (1) HUE045442T2 (enExample)
LT (1) LT2635269T (enExample)
MX (2) MX367209B (enExample)
MY (1) MY160572A (enExample)
NZ (1) NZ609727A (enExample)
PH (2) PH12013500689A1 (enExample)
PL (1) PL2635269T3 (enExample)
PT (1) PT2635269T (enExample)
RS (1) RS59258B1 (enExample)
RU (2) RU2707089C2 (enExample)
SG (1) SG189319A1 (enExample)
SI (1) SI2635269T1 (enExample)
SM (1) SMT201900481T1 (enExample)
WO (1) WO2012060719A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225685A1 (en) 2010-11-04 2013-08-29 Aft Pharmaceuticals Limited Combination composition
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) * 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
CA2963916A1 (en) * 2014-10-06 2016-04-14 Cumberland Pharmaceuticals, Inc. Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
AU2018300075B2 (en) * 2017-07-10 2024-02-29 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση
AU2024281739A1 (en) 2023-06-02 2025-11-27 Ioulia Tseti Pharmaceutical composition comprising ibuprofen
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
DE60114249T2 (de) * 2001-11-02 2006-05-18 Cumberland Pharmaceuticals Inc., Nashville Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure
JP2006514982A (ja) * 2003-03-21 2006-05-18 マクニール−ピーピーシー・インコーポレイテッド 非ステロイド抗炎症薬投薬計画
US20080275125A1 (en) * 2004-07-07 2008-11-06 Aft Pharmaceuticals Limited Combination Composition
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
KR20090094076A (ko) * 2006-10-20 2009-09-03 맥네일-피피씨, 인코포레이티드 아세트아미노펜/이부프로펜 병용물
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
AU2009304002B9 (en) * 2008-10-14 2014-06-26 Aft Pharmaceuticals Limited A medicinal product and treatment
JP2012523377A (ja) * 2009-03-12 2012-10-04 カンバーランド ファーマスーティカルズ インコーポレイテッド 静脈内イブプロフェンの投与
MY164112A (en) * 2010-07-07 2017-11-30 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
US20130225685A1 (en) 2010-11-04 2013-08-29 Aft Pharmaceuticals Limited Combination composition
CA2963916A1 (en) * 2014-10-06 2016-04-14 Cumberland Pharmaceuticals, Inc. Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain

Also Published As

Publication number Publication date
US20130225685A1 (en) 2013-08-29
CN107519159A (zh) 2017-12-29
BR112013010829B1 (pt) 2021-12-21
JP6353577B2 (ja) 2018-07-04
SG189319A1 (en) 2013-05-31
US20230000805A1 (en) 2023-01-05
KR101900520B1 (ko) 2018-09-19
HUE045442T2 (hu) 2019-12-30
US20240207210A1 (en) 2024-06-27
US20250134839A1 (en) 2025-05-01
SI2635269T1 (sl) 2019-10-30
NZ609727A (en) 2015-07-31
LT2635269T (lt) 2019-09-10
PL2635269T3 (pl) 2019-11-29
AU2011324137B2 (en) 2015-05-07
CN103298464A (zh) 2013-09-11
DK2635269T3 (da) 2019-08-26
JP2013541583A (ja) 2013-11-14
EP2635269A4 (en) 2014-09-17
US11446266B2 (en) 2022-09-20
EP2635269B1 (en) 2019-05-22
PH12013500689A1 (en) 2013-05-27
US12220392B2 (en) 2025-02-11
AU2011324137A1 (en) 2013-05-02
CO6771406A2 (es) 2013-10-15
ES2742373T3 (es) 2020-02-14
RU2015103107A3 (enExample) 2018-08-20
CA2814057A1 (en) 2012-05-10
CY1123398T1 (el) 2021-10-29
PH12021550804A1 (en) 2022-02-14
CL2013001250A1 (es) 2013-08-30
MX367209B (es) 2019-07-22
HRP20191489T1 (hr) 2019-11-15
EP2635269A1 (en) 2013-09-11
RU2015103107A (ru) 2015-06-20
US20160235695A1 (en) 2016-08-18
SMT201900481T1 (it) 2019-11-13
KR20140025314A (ko) 2014-03-04
CA2814057C (en) 2022-02-01
MX2013005113A (es) 2013-06-03
BR112013010829B8 (pt) 2022-01-04
BR112013010829A2 (pt) 2016-08-16
MY160572A (en) 2017-03-15
RS59258B1 (sr) 2019-10-31
US20190029982A1 (en) 2019-01-31
WO2012060719A1 (en) 2012-05-10
JP2017132791A (ja) 2017-08-03
US11896567B2 (en) 2024-02-13
RU2707089C2 (ru) 2019-11-22
PT2635269T (pt) 2019-09-04

Similar Documents

Publication Publication Date Title
RU2013123646A (ru) Комбинированная композиция
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
JP2013541583A5 (enExample)
RU2014109074A (ru) ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
RU2010141579A (ru) Режим дозировки селективного агониста рецептора s1p1
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2018507243A5 (enExample)
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
RU2017134443A (ru) Способ лечения с применением традипитанта
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
JP2016505050A5 (enExample)
MX2015014939A (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
RU2009101026A (ru) Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
MY174442A (en) Treating critically ill patients with intravenous ibuprofen
RU2537031C2 (ru) Способ лечения цистита
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
RU2013124994A (ru) КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
RU2007141393A (ru) Способ лечения спастического и болевого синдромов у пациентов с последствиями позвоночно-спинномозговой травмы
RU2010122438A (ru) Противовирусное средство для профилактики и лечения клещевого энцефалита
RU2009125509A (ru) Способ лечения больных с гнойно-воспалительными заболеваниями кожи
Shah et al. Clinical efficacy of a novel new injectable diclofenac formulation designed for intradeltoid use in post-operative pain management

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150406